McDavid Stilwell
Plus aucun poste en cours
Fortune : 179 979 $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Mark Stolper | M | 52 | 3 ans | |
Lee Newcomer | M | 71 | 2 ans | |
Jill O'Donnell-Tormey | M | 68 | 2 ans | |
Charles Newton | M | 53 | 2 ans | |
Bryan Mcmichael | M | 46 | 3 ans | |
Theresa M. LaVallee | M | 57 | 3 ans | |
David Scharfstein | M | 63 |
Harvard Business School
| 21 ans |
Michael Ryan | M | - | 1 ans | |
Rosh Dias | M | - | 2 ans | |
Paul Reider | M | 55 | 3 ans | |
Richard L. Hameister | M | - | 3 ans | |
Karen Kotz | F | - | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Thomas P. Lynch | M | 57 | 3 ans | |
Eckard Weber | M | 73 | 14 ans | |
Lota Zoth | F | 64 | 7 ans | |
Wendy Dixon | M | 68 | 6 ans | |
Aaron Michel | M | - |
Harvard Business School
| 3 ans |
Vincent R. Anicetti | M | 69 | 7 ans | |
David Endicott | M | 58 | 6 ans | |
Monica Forbes | F | 49 | 4 ans | |
Vladimir Vexler | M | 66 | 10 ans | |
John Pontius | M | 68 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 13 ans |
Joseph Hagan | M | 55 | 6 ans | |
Barrington John Albert Furr | M | 80 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 ans |
Mary Szela | F | 61 | 7 ans | |
Deborah Jorn | F | 66 | 2 ans | |
Michael Carter | M | 86 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Jason Shackelford | M | 48 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Alex Sloane | M | - |
Harvard Business School
| 10 ans |
Thomas Cannell | M | 62 | 3 ans | |
Robert Karr | M | 75 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 6 ans |
Michael Powell | M | 69 | 8 ans | |
Dan Turner | M | 62 | 7 ans | |
James Dalton | M | 61 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 ans |
Samuel R. Nussbaum | M | 75 | 3 ans | |
Joseph Lacob | M | 68 | 8 ans | |
James Healy | M | 58 | 8 ans | |
Alan C. Mendelson | M | 76 | - | |
V. Lawlis | M | 72 | 7 ans | |
Kenneth Robinson | M | 69 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Heather Turner | F | 51 | 8 ans | |
Jeffrey G. Hesselberg | M | 65 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Emily johnson lambert | F | - |
Harvard Business School
| 2 ans |
Lea Bajc | F | - |
Harvard Business School
| 2 ans |
Marco Giberti | M | - |
Harvard Business School
| 3 ans |
Edis Jamyn | M | - |
Harvard Business School
| 2 ans |
Yon Sog Choi | M | - |
Harvard Business School
| 2 ans |
Joel M. Podolny | M | - |
Harvard Business School
| 3 ans |
Jonathan T. Pastor | M | - |
Harvard Business School
| 2 ans |
Leslie Feinzaig | F | - |
Harvard Business School
| 2 ans |
Adam Said | M | 40 |
Harvard Business School
| 2 ans |
Stephen Parks | M | - |
Harvard Business School
| 2 ans |
Jose Valentin Pantangco | M | 52 |
Harvard Business School
| 2 ans |
Vanessa Ann Bartram | F | - |
Harvard Business School
| 2 ans |
Mina Pacheco Nazemi | F | - |
Harvard Business School
| 2 ans |
Marc Herdegen | M | - |
Harvard Business School
| 2 ans |
Sherrese Soares | F | 47 |
Harvard Business School
| 2 ans |
Bobby J. Sheth | M | 45 |
Harvard Business School
| 2 ans |
Stephanie Holden | F | - |
Harvard Business School
| 2 ans |
David Dickason | M | - |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 ans |
Morven Groves | F | - |
Harvard Business School
| 2 ans |
Alexis DePree | F | 45 |
Harvard Business School
| 2 ans |
Hector Gil | M | - |
Harvard Business School
| 2 ans |
Aliceson Robinson | M | - |
Harvard Business School
| 2 ans |
Nidhi Chadda | F | - |
Harvard Business School
| 2 ans |
Srdjan Tanjga | M | - |
Harvard Business School
| 2 ans |
David Salanic | M | - |
Harvard Business School
| 2 ans |
Scott Alan Cullerton | M | - |
Harvard Business School
| 2 ans |
Juan Enriquez | M | 64 |
Harvard Business School
| 2 ans |
Christopher M. Busby | M | - |
Harvard Business School
| 2 ans |
Marc André Novakoff | M | 49 |
Harvard Business School
| 2 ans |
Brian Wayne Lemasters | M | - |
Harvard Business School
| 2 ans |
Douglas Simmons | M | - |
Harvard Business School
| 2 ans |
Jason Goins | M | - |
Harvard Business School
| 2 ans |
Craig Stern | M | - |
Harvard Business School
| 2 ans |
David Bordeau | M | - |
Harvard Business School
| 2 ans |
David Matthew Friedman | M | - |
Harvard Business School
| 2 ans |
Eliot E. Kerlin | M | 50 |
Harvard Business School
| 2 ans |
Jill Catherine Raker | F | - |
Harvard Business School
| 2 ans |
Fazeela A. Rashid | F | - |
Harvard Business School
| 2 ans |
Benjamin A. Farkas | M | - |
Harvard Business School
| 3 ans |
Danielle Hootnick | F | - |
Harvard Business School
| 2 ans |
Jeff Swenson | M | 48 |
Harvard Business School
| 2 ans |
John Doran | M | 45 |
Harvard Business School
| 2 ans |
Jeremy A. Lynch | M | - |
Harvard Business School
| 2 ans |
Edward Sobol | M | - |
Harvard Business School
| 2 ans |
Alex Alvarez | M | - |
Harvard Business School
| 2 ans |
Alex Kinnier | M | 48 |
Harvard Business School
| 2 ans |
Nico Iacuzzi | M | - |
Harvard Business School
| 2 ans |
Lee Rand | M | - |
Harvard Business School
| 2 ans |
Laura Grattan | F | 42 |
Harvard Business School
| 2 ans |
Min Zhang | F | 50 |
Harvard Business School
| 2 ans |
So-Youn Song | M | - |
Harvard Business School
| 2 ans |
Dong Hao Yang | M | 52 |
Harvard Business School
| 2 ans |
Alex Popa | M | - |
Harvard Business School
| 2 ans |
Özlem Tekay | F | - |
Harvard Business School
| 4 ans |
Adam Dean Checchi | M | - |
Harvard Business School
| 2 ans |
Samuel Clemens | M | - |
Harvard Business School
| 2 ans |
Lily Surya | F | - |
Harvard Business School
| 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 99 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- McDavid Stilwell
- Réseau Personnel